Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)
NCT04014387Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Jun 2019
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
A Phase 4 trial of suvorexant, zolpidem sublingual tablet in progressive supranuclear palsy (PSP), Insomnia, sponsored by University of California, San Francisco. Started Jun 2019; status: completed.
02
Drugs
suvorexantzolpidem sublingual tablet
03
Conditions
progressive supranuclear palsy (PSP)Insomnia
Beyond the preview
Go deeper on NCT04014387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04014387.